Jamie Christensen - Jan 16, 2024 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
EVP & Chief Scientific Officer
Signature
/s/ John Moriarty, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Jan 16, 2024
Transactions value $
-$94,255
Form type
4
Date filed
1/18/2024, 04:38 PM
Previous filing
Jan 5, 2024
Next filing
Jan 23, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Sale -$57K -966 -0.61% $59.02 157K Jan 16, 2024 Direct F1, F2
transaction MRTX Common Stock Sale -$37.2K -631 -0.4% $59.02 156K Jan 16, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 14, 2022.
F2 Includes 347 shares acquired under the ESPP Purchase on 05/31/2023 and 42 shares acquired under the ESPP purchase on 11/30/2023.
F3 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.